Email Address
Please enter your official email address
We notice that your permissions preference cookie is missing. Please enter your email address so we can determine if you need to complete a permission form or verify that you have already completed this form. Receiving permission from our users is an important part of our compliance with international privacy regulations. Your email address will not be shared without your permission. Please refer to our
privacy policy
for information on how we protect your personal information.
Welcome to AdisInsight
We need some information from you before you start using the platform.
This information will allow us to better understand how AdisInsight is being used.
It does not require or replace the individual login accounts that many of you use to save searches and create email alerts.
Protecting your personal information is important.
That is why AdisInsight collects the minimum amount of information necessary to enable functionality, report usage, and contact you with information about AdisInsight.
For further information on how we protect and process your personal information, please refer to our
privacy policy.
Terms of Service
By accessing or using the AdisInsight platform you agree to the terms of use.
Please select terms of use
How much you and your colleagues use AdisInsight often determines if your organization will continue paying to provide access to the platform.
The number of times you access AdisInsight, the number of searches you performed, and the number of profiles you viewed will be provided to your organization both in aggregate with other users and individually by your email address.
You have the right to opt-out of sharing your email address with your organization but doing so may negatively affect your organization’s decision to renew their subscription to AdisInsight. If you opt-out your email will still be collected for registration purposes.
Please choose your email permissions
Get more from AdisInsight
Keep up to date with all things AdisInsight by signing up to receive our product bulletin, which includes related content from Springer Nature such as white papers, product news, industry commentaries, and webinar invites, straight to your inbox. Unsubscription is always possible via email.
Please choose your permissions
Mandatory field
Please enter your official email address
Research programme: mosquito-borne diseases vaccine - SEEK
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
No
New Molecular Entity
No
Highest Development Phases
No development reported
Parasitic infections; Viral infections; Zika virus infection
Most Recent Events
28 May 2020
No recent reports of development identified for preclinical development in Zika-virus-infection in United Kingdom
16 Jul 2016
No recent reports of development identified for research development in Parasitic-infections(Prevention) in United Kingdom
16 Jul 2016
No recent reports of development identified for research development in Viral-infections(Prevention) in United Kingdom
Development Overview
Introduction
Imutex, a joint venture company of SEEK (formerly PepTcell) and hVIVO, is developing a protein-based vaccine against mosquito-borne diseases, including Zika virus, malaria, dengue and West Nile virus. The company's approach is based on the assumption that exposure to molecules in mosquito saliva could provide immunological protection against infections transmitted by mosquitoes. The company is determining if there are mosquito proteins that are involved in the infection process, and whether a targeted immune response could be induced against such proteins. It is hypothesised that immunisation with the vaccine would provide simultaneous protection against several different mosquito-borne diseases. In addition to providing disease protection in the vaccinated individual, ingestion of blood from the vaccinated individual by a mosquito could interact with antibody targets inside the insect, potentially reducing survival of the mosquito population. Preclinical development is underway in the UK.
In December 2010, PepTcell changed its name to SEEK[1].
As at July 2016, no recent reports of development had been identified for research development in Parasitic-infections (Prevention) in United Kingdom, research development in Viral-infections (Prevention) in United Kingdom.
As at May 2020, no recent reports of development had been identified for preclinical development in Zika-virus-infection in United Kingdom.
Company Agreements
In April 2016, SEEK granted Imutex a worldwide license of the flu and mosquito-borne disease vaccine platforms, and will provide services in exchange for £7 million in cash consideration and a downstream commercialisation royalty[2].
Key Development Milestones
Imutex, in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), plans to conduct a "First in Man" phase I study of Zika virus vaccine in the US[2].
